C90.0
Multiple myeloma
Clinical Classification Guidelines
Inclusion Terms
- Kahler's disease
- Medullary plasmacytoma
- Myelomatosis
- Plasma cell myeloma
Excludes Type 1
- solitary myeloma (C90.3-)
- solitary plasmactyoma (C90.3-)
Medical Intelligence & Overview
Multiple myeloma, also known by various names such as Kahler's disease, medullary plasmacytoma, myelomatosis, or plasma cell myeloma, is a cancer that originates in the plasma cells within the bone marrow. These abnormal plasma cells multiply uncontrollably, leading to various health complications. This condition primarily affects older adults and is characterized by the proliferation of malignant plasma cells that produce abnormal antibodies. These excess cells can accumulate in the bone marrow, weaken bones, impair blood cell production, and interfere with normal immune function.
Causes & Symptoms
Clinical Causes: Genetic mutations in plasma cells Age-related genetic changes Exposure to certain chemicals or radiation Chronic immune system stimulation Family history of blood cancers
Key Symptoms: Bone pain, especially in the back or ribs Fragile bones that break easily Fatigue and weakness Unexplained weight loss Recurrent infections due to immune suppression High levels of calcium in the blood (hypercalcemia) Anemia symptoms like pale skin and shortness of breath Nausea and confusion (in severe cases of hypercalcemia)
Diagnostic & Treatment
Diagnosis Path: Diagnosing multiple myeloma involves a combination of medical evaluations and laboratory tests. These include blood tests to detect abnormal antibodies and calcium levels, urine tests for Bence Jones proteins, and bone marrow biopsies to examine plasma cell density. Imaging studies such as X-rays, MRI, or CT scans are utilized to identify areas of bone damage or lesions. Doctors also assess symptoms and medical history to reach an accurate diagnosis.
Treatment Protocols: While there is no definitive cure for multiple myeloma, several treatment strategies aim to control symptoms, slow disease progression, and improve quality of life. Common treatments include chemotherapy, targeted therapy, immunotherapy, corticosteroids, and sometimes stem cell transplants. Supportive care like bisphosphonates can help strengthen bones, and managing complications such as infections or kidney issues is essential. Treatment plans are individualized based on factors like patient health, disease stage, and response to therapy.
Clinical Advice & FAQs
Billing Guidance
Is C90.0 a billable ICD-10 code?
Yes, C90.0 is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.
Documentation
How do I report C90.0?
Clinical documentation must specify the nature of Multiple myeloma and any associated comorbidities for accurate reporting.
Cite this Clinical Reference
